突觸核蛋白α(SNCa)單克隆抗體
Monoclonal Antibody to Synuclein Alpha (SNCa)
SNC-A; aSYN; PD1; PARK1; PARK4; NACP; Non-A Beta Component Of Alzheimer's Disease Amyloid Precursor Protein; Non-A4 component of amyloid precursor
- 編號MAB222Hu22
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 來源單抗制備
- 宿主小鼠
- 效價(jià)(克隆號)-
- Ig亞型 IgG
- 純化方式抗原特異性親和純化
- 標(biāo)記物無標(biāo)記物
- 免疫原 -
- 緩沖液成份磷酸鹽緩沖液（pH7.4,含有0.02% NaN3和50%甘油）
- 性狀液體
- 濃度1mg/mL
- 且適物種-
- 應(yīng)用WB; IHC; ICC; IP.
如果抗體需用于流式細(xì)胞術(shù)，請參見流式抗體。 - 下載 英文說明書 中文說明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價(jià)格 ¥ 634 ¥ 1478 ¥ 2112 ¥ 5280 ¥ 21120
- 欲了解實(shí)際交易價(jià)格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
該抗體是針對SNCa的小鼠單克隆抗體。在免疫組織化學(xué)染色和免疫印跡實(shí)驗(yàn)中能識別SNCa。
用法
免疫印跡：0.2-2μg/mL;1:500-5000
免疫組織化學(xué)：5-20μg/mL;1:50-200
免疫細(xì)胞化學(xué)：5-20μg/mL;1:50-200
最佳稀釋倍數(shù)最終由用戶決定。
儲存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲，損失率低于5%。
贈品
增值服務(wù)
抗體標(biāo)記定制服務(wù)
Protein-A/G純化柱
細(xì)胞和組織染色液
抗體陽性對照品
組織/切片定制服務(wù)
磷酸化抗體定制服務(wù)
免疫印跡(WB)實(shí)驗(yàn)服務(wù)
免疫組織化學(xué)(IHC)實(shí)驗(yàn)服務(wù)
免疫細(xì)胞化學(xué)(ICC)實(shí)驗(yàn)服務(wù)
流式細(xì)胞術(shù)(FCM)實(shí)驗(yàn)服務(wù)
免疫沉淀(IP)實(shí)驗(yàn)服務(wù)
免疫熒光(IF)實(shí)驗(yàn)服務(wù)
緩沖液
DAB顯色試劑盒
SABC試劑盒
長臂生物素標(biāo)記試劑盒
實(shí)時(shí)熒光定量PCR實(shí)驗(yàn)服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPB222Hu01 | 突觸核蛋白α(SNCa)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAB222Hu01 | 突觸核蛋白α(SNCa)多克隆抗體 | WB; IHC; ICC; IP. |
| LAB222Hu71 | 突觸核蛋白α(SNCa)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| MAB222Hu22 | 突觸核蛋白α(SNCa)單克隆抗體 | WB; IHC; ICC; IP. |
| SEB222Hu | 突觸核蛋白α(SNCa)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| AEB222Hu | 抗突觸核蛋白α抗體(Anti-SNCa)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antibody Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| The Journal of Clinical Investigation | Cerebrospinal fluid–based kinetic biomarkers of axonal transport in monitoring neurodegeneration [PubMed: PMC3428100] |
| Neurobiology of Disease | Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission [PubMed: PMC3107939] |
| Nature Communications | Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus [PubMed: PMC3265381] |
| Provisional chapter | Mutations of PARK Genes and Alpha-Synuclein and Parkin Concentrations in Parkinson’s Disease [Intechopen:Source] |
| Nerodegeneration | Apolipoprotein Eε4: A Biomarker for Executive Dysfunction among Parkinson's Disease Patients with Mild Cognitive Impairment [pubmed:29326545] |
| Experimental gerontology | The anti-aging protein klotho alleviates injury of nigrostriatal dopaminergic pathway in 6-hydroxydopamine rat model of Parkinson's disease: Involvement of PKA/CaMKII/CREB signaling. [pubmed:29107062] |
| Neurobiology of Disease | Development and biochemical characterization of a mouse model of Parkinson's disease bearing defective glucocerebrosidase activity [Pubmed: 30521842] |
| molecular and cellular biochemistry | Potential therapeutic effects of antagonizing adenosine A2A receptor, curcumin and niacin in rotenone-induced Parkinson's disease mice model [Pubmed: 31820278] |
| International Journal of Pharmacology | Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson's disease [Pubmed: 32084576] |
| EBioMedicine | Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys [Pubmed: 32810825] |
